Abstract
Elucidation of the metabolism and pharmacology of 1,2,3-triazolines (TRs) led to the identification of the triazoline pharmacophore and the evolution of the aminoalkylpyridines (AAPs). The AAPs have no activity in the scMet test but are highly effective in the MES seizure test by the oral route. The AAPs bind to the σ1 receptor with low affinity, but high selectivity. They impair Glu release to the same extent as the triazolines and afforded a high degree of protection in the kindled rat. They show no affinity for the NMDA / PCP receptor sites; thus the toxic side effects of NMDA antagonists are absent in the σ selective AAPs. Variations of the heterocyclic unit, the alkyl chain and the amino group in the AAP leads, indicated that the 4-pyridyl substituent along with a methyl (alkyl) group, and a 4-C1, 3-C1 or 3,4-C12 substitution on the N-phenyl group, afforded the most active compounds. Amino group modification by acylation did not improve activity. The hydrazone compounds were the most active. Although the AAPs are very effective in the MES and the kindling models of epilepsy, they showed only low to moderate activity in protecting neuronal cells in stroke-induced cerebral ischemia. In the case of the TR compounds, even the least effective TR afforded 47% protection from neuronal injury. It is not known at this point, whether activity in both the MES and scMet tests, which would imply a role for both Glu and GABA, is a prerequisite for antiischemic activity.
Keywords: aminoalkylpyridines, metabolite analogues, epilepsy, stroke, mes test
Current Medicinal Chemistry
Title: Aminoalkylpyridines (AAPs), Triazoline Metabolite Analogues, As Anticonvulsants Highly Effective in the Mes Test
Volume: 10 Issue: 20
Author(s): Pankaja K. Kadaba and Trupti Dixit
Affiliation:
Keywords: aminoalkylpyridines, metabolite analogues, epilepsy, stroke, mes test
Abstract: Elucidation of the metabolism and pharmacology of 1,2,3-triazolines (TRs) led to the identification of the triazoline pharmacophore and the evolution of the aminoalkylpyridines (AAPs). The AAPs have no activity in the scMet test but are highly effective in the MES seizure test by the oral route. The AAPs bind to the σ1 receptor with low affinity, but high selectivity. They impair Glu release to the same extent as the triazolines and afforded a high degree of protection in the kindled rat. They show no affinity for the NMDA / PCP receptor sites; thus the toxic side effects of NMDA antagonists are absent in the σ selective AAPs. Variations of the heterocyclic unit, the alkyl chain and the amino group in the AAP leads, indicated that the 4-pyridyl substituent along with a methyl (alkyl) group, and a 4-C1, 3-C1 or 3,4-C12 substitution on the N-phenyl group, afforded the most active compounds. Amino group modification by acylation did not improve activity. The hydrazone compounds were the most active. Although the AAPs are very effective in the MES and the kindling models of epilepsy, they showed only low to moderate activity in protecting neuronal cells in stroke-induced cerebral ischemia. In the case of the TR compounds, even the least effective TR afforded 47% protection from neuronal injury. It is not known at this point, whether activity in both the MES and scMet tests, which would imply a role for both Glu and GABA, is a prerequisite for antiischemic activity.
Export Options
About this article
Cite this article as:
Kadaba K. Pankaja and Dixit Trupti, Aminoalkylpyridines (AAPs), Triazoline Metabolite Analogues, As Anticonvulsants Highly Effective in the Mes Test, Current Medicinal Chemistry 2003; 10 (20) . https://dx.doi.org/10.2174/0929867033456819
DOI https://dx.doi.org/10.2174/0929867033456819 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer’s Disease
Current Pharmaceutical Design Prediction of an Interaction between Bakuchiol and Acetylcholinesterase using Adaboost
Current Bioinformatics Madecassic Acid Reduces Fast Transient Potassium Channels and Promotes Neurite Elongation in Hippocampal CA1 Neurons
CNS & Neurological Disorders - Drug Targets Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology The Role of <i>Eif2s3y</i> in Mouse Spermatogenesis and ESC
Current Stem Cell Research & Therapy Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets Pediatric Epilepsy Surgery: Neuropsychological and Psychosocial Outcomes
Current Pediatric Reviews Preparation, Characterization and in vivo Evaluation of Simple Monolithic Ethylcellulose-coated Pellets Containing Topiramate with Biphasic Release Characteristics
Current Drug Delivery N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Potassium Channels (Guest Editor: Dr. Vincenzo Calderone)]
Current Topics in Medicinal Chemistry Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings
Current Drug Discovery Technologies Metabolism of Drugs Used in the Therapy of Seizures: An Analytical Point of View. Part 1
Current Drug Metabolism Low-Dose Mercury Exposure in Early Life: Relevance of Thimerosal to Fetuses, Newborns and Infants
Current Medicinal Chemistry Formulation of Extended-Release Beads of Lamotrigine Based on Alginate and <i>Cassia fistula</i> Seed Gum by QbD Approach
Current Drug Delivery Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued)